Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HIV-1 Env Model Immunogens Prime-Boost Study
NCT03816137Phase 1Completed
- Sponsor
- Imperial College London
- Start
- Mar 2019
- Primary completion
- Dec 2022
- Modality
- Nanoparticles, Recombinant Proteins and Enzymes, Therapeutic Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised trial of ConM SOSIP, ConS UFO, mosaic sosips, AMC011 SOSIP and 763 SOSIP in human immunodeficiency virus infection (HIV) (13 arms), sponsored by Imperial College London. Primary endpoints: Neutralising antibodies to virus expressing ConM and ConS envelopes at 6 months, Neutralising antibodies to virus expressing Mosaic envelopes at 12 months and 1 more. Started Mar 2019; status: completed.
02
Drugs
ConM SOSIPConS UFOmosaic sosipsAMC011 SOSIP763 SOSIP
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT03816137.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03816137.